Haohai Biological Technology

Shanghai Haohai Biological Technology Co., Ltd. (06826.HK, 688366.SH) is a high-tech biomedical enterprise specializing in the research, production, and sales of medical biomaterials. The company strategically focuses on rapidly growing therapeutic areas within the medical biomaterials market, including ophthalmology, plastic surgery and wound care, orthopedics, anti-adhesion, and hemostasis. Its current product portfolio mainly includes intraocular lens series, medical hyaluronic acid/sodium hyaluronate series, medical chitosan series, medical collagen sponge series, and external recombinant human epidermal growth factor series. Based on the sales volume of intraocular lenses and the number of cataract surgeries performed nationwide, the company's share of the Chinese intraocular lens market reached approximately 30% in 2019. Additionally, the company has long maintained a leading position in niche fields such as surgery, ophthalmology, and orthopedics. According to a research report published by Guangzhou Benchmarking Medical Information Co., Ltd. in 2020, Haohai Biological Technology’s ophthalmic viscoelastic agents, orthopedic joint cavity visco-supplements, surgical anti-adhesion agents, and external recombinant human epidermal growth factors held market shares of 45.85%, 42.06%, 29.64%, and 23.49%, respectively, in 2019. While solidifying its leading position in niche markets, Haohai Biological Technology continues to increase R&D investment, currently owning 30 core technologies and patented products in the biopharmaceutical field, relying on technological innovation as the engine for future corporate development. As of December 31, 2019, the company had 263 R&D technical personnel globally, with a national-level corporate technology center, a national-level postdoctoral research workstation, two national-level R&D platforms, multiple provincial and ministerial-level technology and R&D transformation platforms, and a Shanghai academician expert workstation. It has established an integrated collaborative R&D system in China, the United States, and the United Kingdom, forming an initial international and domestic integrated R&D layout. Moreover, the company’s products and technologies have twice won the Second Prize of the National Science and Technology Progress Award and have been granted nearly 50 invention patents.